U.S. markets open in 5 hours 32 minutes
  • S&P Futures

    3,920.75
    -1.75 (-0.04%)
     
  • Dow Futures

    31,967.00
    +51.00 (+0.16%)
     
  • Nasdaq Futures

    13,243.00
    -59.00 (-0.44%)
     
  • Russell 2000 Futures

    2,297.00
    +11.90 (+0.52%)
     
  • Crude Oil

    63.70
    +0.48 (+0.76%)
     
  • Gold

    1,789.30
    -8.60 (-0.48%)
     
  • Silver

    27.91
    +0.05 (+0.18%)
     
  • EUR/USD

    1.2209
    +0.0040 (+0.33%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.75
    -1.36 (-5.88%)
     
  • GBP/USD

    1.4152
    +0.0011 (+0.08%)
     
  • USD/JPY

    106.1070
    +0.2250 (+0.21%)
     
  • BTC-USD

    49,964.66
    -194.66 (-0.39%)
     
  • CMC Crypto 200

    996.74
    +2.08 (+0.21%)
     
  • FTSE 100

    6,687.59
    +28.62 (+0.43%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

  • Oops!
    Something went wrong.
    Please try again later.
Unity Biotechnology, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from December 1, 2020 through December 15, 2020, the Board of Directors (the “Board”) granted 2 new employees stock-based awards covering an aggregate of 103,000 shares of UNITY common stock, including options to purchase an aggregate of 103,000 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

CONTACT: Media Canale Communications Jason Spark jason.spark@canalecomm.com